The average price point forecasted by analysts for MyMD Pharmaceuticals Inc (MYMD) is $1536.00, which is $31.7 above the current market price. The public float for MYMD is 37.52M, and currently, short sellers hold a 8.73% ratio of that float. The average trading volume of MYMD on November 15, 2023 was 595.01K shares.

MYMD) stock’s latest price update

MyMD Pharmaceuticals Inc (NASDAQ: MYMD)’s stock price has dropped by -11.27 in relation to previous closing price of 0.34. Nevertheless, the company has seen a loss of -9.12% in its stock price over the last five trading days. Business Wire reported 2023-08-02 that BALTIMORE–(BUSINESS WIRE)–MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or the “Company”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced statistically significant positive topline Phase 2 results for its next generation Oral TNF-α inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty earlier this week. In conjunction with its release, the company also announced it will hold a confer.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


MYMD’s Market Performance

MyMD Pharmaceuticals Inc (MYMD) has experienced a -9.12% fall in stock performance for the past week, with a -35.78% drop in the past month, and a -73.46% drop in the past quarter. The volatility ratio for the week is 8.87%, and the volatility levels for the past 30 days are at 11.52% for MYMD. The simple moving average for the last 20 days is -22.20% for MYMD’s stock, with a simple moving average of -77.88% for the last 200 days.

MYMD Trading at -38.81% from the 50-Day Moving Average

After a stumble in the market that brought MYMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.93% of loss for the given period.

Volatility was left at 11.52%, however, over the last 30 days, the volatility rate increased by 8.87%, as shares sank -29.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -63.57% lower at present.

During the last 5 trading sessions, MYMD fell by -10.58%, which changed the moving average for the period of 200-days by -89.07% in comparison to the 20-day moving average, which settled at $0.3792. In addition, MyMD Pharmaceuticals Inc saw -73.92% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at MYMD starting from Rivard Paul, who purchase 150,000 shares at the price of $1.11 back on Aug 24. After this action, Rivard Paul now owns 400,000 shares of MyMD Pharmaceuticals Inc, valued at $166,500 using the latest closing price.

Rivard Paul, the Chief Legal Officer of MyMD Pharmaceuticals Inc, purchase 25,000 shares at $1.12 during a trade that took place back on Aug 17, which means that Rivard Paul is holding 250,000 shares at $28,080 based on the most recent closing price.

Stock Fundamentals for MYMD

The total capital return value is set at -79.12, while invested capital returns managed to touch -78.92. Equity return is now at value -94.99, with -59.08 for asset returns.

Based on MyMD Pharmaceuticals Inc (MYMD), the company’s capital structure generated 0.96 points at debt to equity in total, while total debt to capital is 0.96. Total debt to assets is 0.81, with long-term debt to equity ratio resting at 0.52. Finally, the long-term debt to capital ratio is 0.51.

The liquidity ratio also appears to be rather interesting for investors as it stands at 1.95.


To put it simply, MyMD Pharmaceuticals Inc (MYMD) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.